Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K+ -ATPase subunitst

Yun Lin1, Dah H Ho, Robert A Newman

  • 1Department of Experimental Therapeutics, The Univ. of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. liny2@mail.nih.gov

Insights

Cardiac glycosides may treat cancer by inhibiting Na+, K+-ATPase. High Na+, K+-ATPase alpha 1 expression correlates with cancer cell resistance, suggesting a therapeutic target for cancer therapy.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • The membrane enzyme Na+, K+-ATPase maintains ion homeostasis.
  • Emerging roles suggest Na+, K+-ATPase inhibition by cardiac glycosides could benefit cancer patients.

Purpose of the Study:

  • To investigate determinants of human tumor cell sensitivity to cardiac glycosides.
  • To explore the role of Na+, K+-ATPase isoforms in cancer cell proliferation and survival.

Main Methods:

  • Utilized twelve human tumor cell lines and in vitro cell culture models (glioma, melanoma).
  • Assessed Na+, K+-ATPase alpha 1 and alpha 3 isoform expression levels.
  • Measured cellular glutathione content, cytochrome c release, and caspase activation.

Main Results:

  • High Na+, K+-ATPase alpha 1 and low alpha 3 expression correlated with resistance to cardiac glycosides.
  • Increased Na+, K+-ATPase alpha 1 activity linked to higher glutathione levels.
  • Resistance involved delayed cytochrome c release and caspase activation, promoting colony formation and survival.

Conclusions:

  • Na+, K+-ATPase alpha 1 isoform appears crucial for tumor growth and survival.
  • Targeting Na+, K+-ATPase alpha 1 with cardiac glycosides presents a potential cancer therapy strategy.